Fibresolve
Payments companies reported to CMS as associated with Fibresolve. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Fibresolve, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Fibresolve
These are the largest totals companies reported as associated with Fibresolve. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sunil Santhanakrishnan | Phoenix, AZ | Pulmonary Disease | $434.33 |
| Robert Cobb | Tucson, AZ | Pulmonary Disease | $314.35 |
| Michael Czarnecki | Washington, DC | Internal Medicine | $236.52 |
| James Pharaoh | Knoxville, TN | Pulmonary Disease | $236.52 |
| Eric Weaver | Knoxville, TN | Pulmonary Disease | $200.11 |
Prescribed Fibresolve?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.